Copyright © 2004 by the European Society of Cardiology.
Clinical research
Trimetazidine improves left ventricular function and quality of life in elderly patients with coronary artery disease
a Cardiovascular Research Unit, Department of Medical Sciences, San Raffaele — TOSINVEST SANITA', via della Pisana 235, 00139 Roma, Italy
b Department of Geriatric Cardiology, InCOR, University of Sao Paulo Medical School, Sao Paulo, Brazil
Received December 1, 2003; revised June 13, 2004; accepted June 17, 2004 * Corresponding author. Tel.: +39-3358097652/6-660581; fax: +39-6-66058300 (E-mail: giuseppe.rosano{at}sanraffaele.it).
See page 1765 for the editorial comment on this article (doi:10.1016/j.ehj.2004.08.019)
AIM: Elderly patients have an increased incidence of ischaemic dilated cardiomyopathy often related to diffuse coronary artery disease. Trimetazidine protects ischaemic myocardium by improving the myocardial energy utilisation during myocardial ischaemia. Aim of the present study was to evaluate the effects of trimetazidine on left ventricular (LV) function in elderly patients with ischaemic heart disease and reduced LV function.
METHODS: Forty seven elderly patients (40 males and 7 females, mean age 78±3 years) were randomised to receive, in addition to standard therapy, either trimetazidine or placebo and were evaluated by echocardiography at baseline and after 6 months.
RESULTS: Trimetazidine and placebo had no effect on either blood pressure or heart rate (SBP 2±5 vs 4±6 mmHg, DBP –1±6 vs 3±4 mmHg, HR –3±7 vs 5±9 bpm, trimetazidine and placebo compared to baseline, respectively). At the end of the study patients randomised to trimetazidine showed a significant greater left ventricular function and smaller left ventricular diastolic and systolic diameters and volume indices compared to patients receiving placebo (LVEF: 34.4±2.3% vs 27±2.8%, p<0.0001; LVEDD: 58.6±1.9 mm vs 64±1.7 mm, p<0.0001; LVESD: 44.5±1.1 vs 50±0.8 mm, p<0.0001). A significant smaller wall motion score index was detected in trimetazidine-treated patients compared to those allocated to placebo (1.24±0.12 vs 1.45±0.19, p<0.01), the percentage change in LVEF compared to baseline was also significantly greater in trimetazidine-treated patients. Diastolic function significantly improved in the trimetazidine group while it remained unchanged in the placebo group. At follow-up evaluation, patients receiving trimetazidine showed a greater improvement in angina and NYHA class than patients allocated to placebo. Quality of life significantly improved in all patients treated with trimetazidine while remained unchanged in those allocated to placebo.
CONCLUSION: In elderly patients with ischaemic cardiomyopathy trimetazidine in addition to standard medical therapy has a beneficial effect on LV systolic and diastolic function, and improves quality of life.
CiteULike 
Connotea 
Del.icio.us What's this?
Related articles in EHJ:
- Metabolic therapy for heart failure
- M. Faadiel Essop and Lionel H. Opie
EHJ 2004 25: 1765-1768.[Extract] [FREE Full Text]
This article has been cited by other articles:
|
|
 |
|
  H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy Circulation, September 16, 2008; 118(12): 1250 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Neglia, A. De Caterina, P. Marraccini, A. Natali, M. Ciardetti, C. Vecoli, A. Gastaldelli, D. Ciociaro, P. Pellegrini, R. Testa, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3270 - H3278. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF]
|
|
|
|
|
|
P. Knaapen, T. Germans, J. Knuuti, W. J. Paulus, P. A. Dijkmans, C. P. Allaart, A. A. Lammertsma, and F. C. Visser Myocardial Energetics and Efficiency: Current Status of the Noninvasive Approach Circulation, February 20, 2007; 115(7): 918 - 927. [Full Text] [PDF]
|
|
|
|
|
|
H. Tuunanen, E. Engblom, A. Naum, K. Nagren, B. Hesse, K. E. J. Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, L. H. Opie, et al. Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure Circulation, November 14, 2006; 114(20): 2130 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W.H. W. Tang Metabolic Approach in Heart Failure: Rethinking How We Translate From Theory to Clinical Practice J. Am. Coll. Cardiol., September 5, 2006; 48(5): 999 - 1000. [Full Text] [PDF]
|
|
|
|
|
|
G. Fragasso, A. Palloshi, P. Puccetti, C. Silipigni, A. Rossodivita, M. Pala, G. Calori, O. Alfieri, and A. Margonato A Randomized Clinical Trial of Trimetazidine, a Partial Free Fatty Acid Oxidation Inhibitor, in Patients With Heart Failure J. Am. Coll. Cardiol., September 5, 2006; 48(5): 992 - 998. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. D. Monti, E. Setola, G. Fragasso, R. P. Camisasca, P. Lucotti, E. Galluccio, A. Origgi, A. Margonato, and P. Piatti Metabolic and endothelial effects of trimetazidine on forearm skeletal muscle in patients with type 2 diabetes and ischemic cardiomyopathy Am J Physiol Endocrinol Metab, January 1, 2006; 290(1): E54 - E59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and I. C. Okere Metabolic therapies for heart disease: Fish for prevention and treatment of cardiac failure? Cardiovasc Res, November 1, 2005; 68(2): 175 - 177. [Full Text] [PDF]
|
|
|
|
|
|
M. Faadiel Essop and L. H. Opie Metabolic therapy for heart failure Eur. Heart J., October 2, 2004; 25(20): 1765 - 1768. [Full Text] [PDF]
|
|